ArticleFrontiers in public health2025
Balancing innovation and affordability in relapsing-remitting multiple sclerosis: a budget impact analysis from Saudi Arabia.
Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Relapsing-Remitting Multiple Sclerosis (RRMS) is the most prevalent form of multiple sclerosis, characterized by episodic neurological deterioration and recovery. The rising burden of RRMS in Saudi Arabia, underscores the need for cost-effective treatment strategies. This study evaluates the economic impact of disease-modifying therapies (DMTs) for RRMS from a national healthcare payer perspective, with a focus on the role of managed entry agreements (MEAs) in optimizing affordability. Methods: A budget impact analysis was conducted using an Excel-based model over a 5-year period. The model incorporated real-world uptake scenarios derived from expert opinion and hypothetical 100% uptake. The eligible population was stratified by treatment status and disease severity. Costs included drug acquisition, administration, monitoring, relapse management, and adverse event management. Scenarios with and without MEAs were analyzed to estimate net budget impact. Results: MEAs were associated with reduced treatment and relapse-related costs across all patient subgroups. Ofatumumab showed favorable economic profiles under MEA conditions, while cladribine (Mavenclad®) emerged as the most cost-efficient option. Siponimod (without MEA) in Active RRMS naïve (100% uptake) resulted in the highest overall expenditure, totaling SAR 732,484,106.83, highlighting the importance of strategic pricing and reimbursement models for high-cost DMTs in RRMS. Conclusion: This is the first comprehensive exploratory economic evaluation comparing first-in-class RRMS therapies in Saudi Arabia. Findings support the adoption of MEAs and performance-based reimbursement to ensure sustainable RRMS care in resource-constrained settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.